Administrative Head, Biomedical Sciences and Assistant Dean for Research; Cooper Medical School of Rowan University
Renowned for his work on cell death in health and disease, Boehning’s work has illustrated the central role of the IP3 receptor calcium channel in mediating apoptotic cell death. He found that the IP3 receptor is essential to the progression of most cell death paradigms, and how this channel is activated during disease. Of note, Dr. Boehning discovered how this receptor contributes to apoptotic resistance in lymphoma and other cancers. His basic science approaches have also developed new therapeutic agents for inhibiting cell death by blocking IP3 receptor activity. Finally, in collaboration with clinical faculty he has shown in laboratory models and in human patients that increased IP3 receptor activity after traumatic injury leads to systemic inflammation and type II diabetes (so called “stress-induced diabetes”) which contributes to morbidity and mortality. These “bench to bedside” approaches may lead to new therapeutics for improving patient survival. Indeed, cell permeant peptides developed by Dr. Boehning which block IP3 receptor activation during cell death are currently being examined in pre-clinical models of traumatic injury.
Boehning earned his PhD in cell biology from Thomas Jefferson University in Philadelphia, where he was a Foerderer Fellow. His work was recognized with the Alumni Thesis Award for the top thesis of his graduating year. Boehning also completed a post-doctoral fellowship in the Department of Neuroscience at Johns Hopkins University.
A National Institutes of Health (NIH)-funded researcher, Boehning’s findings have been published in over 50 papers in top scientific journals. He is currently the principal investigator or co-investigator on three NIH grants to study cell signaling in health and disease. In addition, he has served on many study section panels including continuous service on the American Heart Association Molecular Signaling study section since 2009 and many ad hoc panels at the NIH, National Science Foundation, Alzheimer’s Association, Italian Ministry of Health, and others. He is also very active in scientific outreach activities, including lecturing at local schools and lobbying at the local to national level for scientific education and funding.
×
About Darren Boehning
Renowned for his work on cell death in health and disease, Boehning’s work has illustrated the central role of the IP3 receptor calcium channel in mediating apoptotic cell death. He found that the IP3 receptor is essential to the progression of most cell death paradigms, and how this channel is activated during disease. Of note, Dr. Boehning discovered how this receptor contributes to apoptotic resistance in lymphoma and other cancers. His basic science approaches have also developed new therapeutic agents for inhibiting cell death by blocking IP3 receptor activity. Finally, in collaboration with clinical faculty he has shown in laboratory models and in human patients that increased IP3 receptor activity after traumatic injury leads to systemic inflammation and type II diabetes (so called “stress-induced diabetes”) which contributes to morbidity and mortality. These “bench to bedside” approaches may lead to new therapeutics for improving patient survival. Indeed, cell permeant peptides developed by Dr. Boehning which block IP3 receptor activation during cell death are currently being examined in pre-clinical models of traumatic injury.
Boehning earned his PhD in cell biology from Thomas Jefferson University in Philadelphia, where he was a Foerderer Fellow. His work was recognized with the Alumni Thesis Award for the top thesis of his graduating year. Boehning also completed a post-doctoral fellowship in the Department of Neuroscience at Johns Hopkins University.
A National Institutes of Health (NIH)-funded researcher, Boehning’s findings have been published in over 50 papers in top scientific journals. He is currently the principal investigator or co-investigator on three NIH grants to study cell signaling in health and disease. In addition, he has served on many study section panels including continuous service on the American Heart Association Molecular Signaling study section since 2009 and many ad hoc panels at the NIH, National Science Foundation, Alzheimer’s Association, Italian Ministry of Health, and others. He is also very active in scientific outreach activities, including lecturing at local schools and lobbying at the local to national level for scientific education and funding.
| Present | Assistant Dean for Research, Rowan University ‐ Cooper Medical School of Rowan University | |
|
|
||
